This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).
An example of artificial intelligence-aided clinical decision support software for a heart failure patient from the vendor HealthReveal. The AI pulled in relevant patient data from the electronic medical record and offers recommendations for care based on current American Heart Association (AHA) guidelines. It also offers the citations for where to find the guidelines and prescribing information for the recommended drug.
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s (AHA) 2018 Scientific Sessions this week. Chicago. It provides evidence-based recommendations for youth ages three through 17 and adults to safely get the physical activity and was a major topic of discussion. Pictured here is Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance, presenting on the main stage at AHA, with details relat d to the new guidelines.
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.